A

Aclaris Therapeutics
D

ACRS

4.31000
USD
-0.25
(-5.48%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-8
Market Cap
601,950,461
Overview
Related Instruments
A
ADUS
95.690 USD
1.240
(1.31%)
A
AIHS
1.32000 USD
0.01000
(0.76%)
A
ALXO
1.65000 USD
0.04500
(2.80%)
BMY
BMY
58.715 USD
-0.305
(-0.52%)
C
CAPR
35.280 USD
1.420
(4.19%)
C
CGC
1.18000 USD
-0.03000
(-2.48%)
C
CHRS
1.74500 USD
-0.03000
(-1.69%)
C
CRIS
0.57020 USD
-0.04400
(-7.16%)
C
CVM
3.19000 USD
-0.08000
(-2.45%)
F
FATE
1.34000 USD
0.01000
(0.75%)
G
GOSS
0.36370 USD
-0.01090
(-2.91%)
I
INO
1.14500 USD
0.00000
(0.00%)
J
JAZZ
196.490 USD
-3.430
(-1.72%)
K
KALA
0.13630 USD
-0.01700
(-11.09%)
K
KURA
9.26500 USD
-0.02500
(-0.27%)
M
MBRX
2.54000 USD
0.00000
(0.00%)
M
MGNX
3.20000 USD
0.01000
(0.31%)
MRNA
MRNA
50.710 USD
-2.130
(-4.03%)
N
NKTR
91.580 USD
0.380
(0.42%)
R
RARE
24.090 USD
-0.180
(-0.74%)
S
SRPT
20.270 USD
-0.135
(-0.66%)
S
STOK
34.010 USD
-0.930
(-2.66%)
V
VCEL
35.616 USD
1.226
(3.57%)
W
WVE
7.18000 USD
-0.12000
(-1.64%)
More

Title: Aclaris Therapeutics

Sector: Healthcare
Industry: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android
Social Network
The NetworkSignals NetworkIdeas NetworkBest TradersUser Reviews for Brokers
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHouse rulesHelp Centeradvertising with ArincenOur servicesReferral programDownload Mobile App
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.